No Detail Found!

Effects of radical surgery, chemotherapy combined with PD-1 inhibitor camrelizumab on prognosis of hilar cholangiocarcinoma patients and its clinical significance

Author(s)
Yuchen Liu Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College,Nanchong,China;Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College,Nanchong,China
Jianjiao Zhu Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College,Nanchong,China;Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College,Nanchong,China
Fanning Xie Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College,Nanchong,China;Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College,Nanchong,China
Jilin Tao Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College,Nanchong,China;Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College,Nanchong,China
Jingdong Li Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College,Nanchong,China;Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College,Nanchong,China
Abstract
Hilar cholangiocarcinoma (HCCA), a malignant bile duct tumor, has an obscure pathogenesis. We aimed to assess the therapeutic effects of surgery and chemotherapy combined with the PD-1 inhibitor camrelizumab on HCCA patients' prognosis. This study included 26 HCCA patients. Post-surgery, patients received camrelizumab (3mg/kg IV) every 3 weeks, oxaliplatin (100 mg/m2) weekly and gemcitabine (1000 mg/m2) biweekly. Computed tomography assessed treatment response after 6 weeks and survival was evaluated through quarterly follow-ups. Among the 26 patients, 2 achieved complete response, 9 partial response, and 5 stable disease, while 10 progressed. The objective response rate (ORR) and disease control rate (DCR) were 42.3% and 61.5%, respectively. Successful down staging was observed in 16 patients. Post-treatment, AST and ALT levels significantly increased. The overall survival (OS) and disease-free survival (DFS) rates were 76.9% and 69.2%, respectively. Sensitive patients (with down staging) had significantly better survival than non-sensitive patients. Radical surgery and chemotherapy combined with camrelizumab may be effective and safe for HCCA management. Statistical analyses were performed using GraphPad Prism version 7.0, employing Student's t-tests for comparisons between groups.
Publication Details
Page(s) 1110-1116
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
chemotherapy, Camrelizumab, radical surgery, HCCA, hilar cholangiocarcinoma
References
Considerations of Hilar Cholangiocarcinoma. Surg. Oncol. Clin. N.,Am Cholangiocarcinoma. Surg. Oncol. Clin. N. . .. , 28(4) : 601-617.
Botticelli A,Cirillo A,Strigari L,Valentini F,Cerbelli B,Scagnoli S,Cerbelli E,Zizzari IG,Rocca CD,D'Amati G,Polimeni A,Nuti M,Merlano MC,Mezi S,Marchetti P .2021 .Anti-PD-1 and anti-PD-L1 in head and neck cancer: A network meta-analysis. Front Immunol, 12 : 705096.
Budimir N,Thomas GD,Dolina JS,Salek-Ardakani S .2022 .Reversing T-cell exhaustion in cancer: Lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol. Res., 10(2) : 146-153.
Edeline J,Touchefeu Y,Guiu B,Farge O,Tougeron D,Baumgaertner I,Ayav A,Campillo-Gimenez B,Beuzit L,Pracht M,Lièvre A,Le Sourd S,Boudjema K,Rolland Y,Boucher E,Garin E .2020 .Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol., 6(1) : 51-59.
Elvevi A,Laffusa A,Scaravaglio M,Rossi RE,Longarini R,Stagno AM,Cristoferi L,Ciaccio A,Cortinovis DL,Invernizzi P,Massironi S P .2022 .Clinical treatment of cholangiocarcinoma: An updated comprehensive review. , 27(5) : 100737.
Forde PM,Chaft JE,Smith KN,Anagnostou V,Cottrell TR,Hellmann MD,Zahurak M,Yang SC,Jones DR,Broderick S,Battafarano RJ,Velez MJ,Rekhtman N,Olah Z,Naidoo J,Marrone KA,Verde F,Guo H,Zhang J,Caushi JX,Chan HY,Sidhom JW,Scharpf RB,White J,Gabrielson E,Wang H,Rosner GL,Rusch V,Wolchok JD,Merghoub T,Taube JM,Velculescu VE,Topalian SL,Brahmer JR,Pardoll DM .2018 .Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med, 378(21) : 1976-1986.
Goyal L,Kongpetch S,Crolley VE,Bridgewater J .2021 .Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat. Rev., 95 : 102170.
Kelley RK,Ueno M,Yoo C,Finn RS,Furuse J,Ren Z,Yau T,Klümpen HJ,Chan SL,Ozaka M,Verslype C,Bouattour M,Park JO,Barajas O,Pelzer U,Valle JW,Yu L,Malhotra U,Siegel AB,Edeline J,Vogel A,Investigators A .2023 .Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. , 401(10391) : 1853-1865.
Klein O,Kee D,Nagrial A,Markman B,Underhill C,Michael M,Jackett L,Lum C,Behren A,Palmer J,Tebbutt NC,Carlino MS,Cebon J .2020 .Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol., 6(9) : 1405-1409.
Kong Y,Zhao X,Xu M,Pan J,Ma Y,Zou L,Peng Q,Zhang J,Su C,Xu Z,Zhou W,Peng Y,Yang J,Zhou C,Li Y,Guo Q,Chen G,Wu H,Xing P,Zhang L P .2022 .PD-1 inhibitor combined with radiotherapy and gm-csf (prag) in patients with metastatic solid tumors: An open-label phase II study. , 13 : 952066.
Lee JW,Zhang Y,Yoshizawa T,Argani P,Wood LD,Oshima K LD .2022 .Cancerization of ducts in hilar cholangiocarcinoma. Virchows, 481(2) : 1-10.
Li Q,Han J,Yang Y,Chen Y Y .2022 .PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol, 13 : 1070961.
Marabelle A,Le DT,Ascierto PA,Di Giacomo AM,De Jesus-Acosta A,Delord JP,Geva R,Gottfried M,Penel N,Hansen AR,Piha-Paul SA,Doi T,Gao B,Chung HC,Lopez-Martin J,Bang YJ,Frommer RS,Shah M,Ghori R,Joe AK,Pruitt SK,Diaz LA,Study LA,Clin LA .2020 .Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-. , 38(1) : 1-10.
Quinn LM,Haldenby S,Antzcak P,Fowler A,Bullock K,Kenny J,Gilbert T,Andrews T,Diaz-Nieto R,Fenwick S,Jones R,Costello-Goldring E,Poston G,Greenhalf W,Palmer D,Malik H,Goldring C H .2023 .Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Sci. Rep, 13(1) : 6681.
Rizvi S,Khan SA,Hallemeier CL,Kelley RK,Gores GJ .2018 .Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol., 15(2) : 95-111.
Soares KC,Jarnagin WR .2021 .. The Landmark Series: Hilar Cholangiocarcinoma. Ann. Surg, 28(8) : 4158-4170.
Xia T,Li K,Niu N,Shao Y,Ding D,Thomas DL,Jing H,Fujiwara K,Hu H,Osipov A,Yuan C,Wolfgang CL,Thompson ED,Anders RA,He J,Mou Y,Murphy AG,Zheng L AG .2022 .Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J. Hematol. Oncol., 15(1) : 37.
Zhang MY,Luo M,Wang JP .2022 .FXR expression in rats of hilar cholangiocarcinoma. Sci. Rep, 12(1) : 8741.
Zhang MY,Wang JP,He K,Xia XM .2021 .Bsep expression in hilar cholangiocarcinoma of rat model. Sci. Rep, 11(1) : 2861.
Zhao Q,Chen Y,Du S,Yang X,Chen Y,Ji Y,Zeng Z Y .2021 .Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: Reflection from four cases. Cancer Biol, 22(3) : 175-183.
0

Citations

0

Downloads

64

Views